CVS Caremark Adds Foundayo June 1, Zepbound October 1 with Co-Preferred Status
NVO•CVS Caremark will restore Eli Lilly’s Zepbound coverage on October 1 and add its oral weight‐loss pill Foundayo to standard commercial formularies on June 1, affecting 25–30 million members. Under the new co‐preferred arrangement, Novo Nordisk’s Wegovy injection and oral pill retain preferred status, while CVS projects 10–15% lower weight‐management drug spending.
1. Coverage Restoration Timeline
CVS Caremark will reinstate coverage for Zepbound on October 1 and introduce Lilly’s oral weight‐loss pill Foundayo to its standard commercial formularies on June 1, encompassing roughly 25–30 million members under the template.
2. Co-Preferred Arrangement
Under the revised formulary, Novo Nordisk’s Wegovy injection and oral pill will hold equal, co‐preferred status alongside Zepbound and Foundayo, ensuring no access disruption for existing Wegovy patients.
3. Projected Spending Reduction
CVS projects the restructured weight‐management drug lineup will reduce spending by 10–15%, reflecting negotiated pricing adjustments across both manufacturers’ obesity treatments.
4. Pricing and Access Details
Zepbound carries a list price of $1,086 per month with potential copays as low as $25 for privately insured patients, while both companies offer their lowest pill doses at $149 per month; Foundayo requires no food timing restrictions, unlike the Wegovy pill.
